Mode
Text Size
Log in / Sign up

Nirmatrelvir-ritonavir showed no reduction in hospitalization or death within 28 days for higher-risk adults in community trialsNew Study Questions Early Use of Paxlovid for Vaccinated Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that nirmatrelvir-ritonavir did not reduce hospitalization or death in higher-risk adults within 28 days in these trials.

This analysis evaluated the impact of nirmatrelvir-ritonavir versus usual care alone in higher-risk adults who tested positive for SARS-CoV-2 and had symptoms for five days or less. The intervention involved taking the medication twice daily for five days in a community setting. The primary outcome assessed was hospitalization or death from any cause within 28 days after randomization.

The results indicated that the addition of the antiviral regimen did not reduce the incidence of the primary composite outcome. Although secondary data suggested a reduction in viral load by the end of treatment, this did not translate into a benefit regarding severe clinical events in the overall population studied. The trials were conducted as open-label platform studies, which may influence interpretation of efficacy.

The authors highlight significant limitations regarding the uncertainty of effectiveness in persons who have been vaccinated, infected naturally, or both. Serious adverse events were observed in a small number of participants across the trials. Consequently, the clinical relevance for this specific population is tempered by the lack of observed benefit in preventing severe outcomes within the short follow-up period.

A Common Dilemma

Imagine you have been vaccinated against the flu. You get a cold, and you wonder if you need strong medicine to fight it off. Now, imagine that same logic applied to the coronavirus.

For a long time, doctors told everyone to take the pill Paxlovid (nirmatrelvir-ritonavir) as soon as they tested positive. This advice was based on older data from unvaccinated people who were very sick.

But the world has changed. Most adults are now vaccinated. Many have also had the virus before. So, does that same pill still work the same way?

The coronavirus is still around. It causes serious trouble for older adults and those with health problems like heart disease or diabetes.

Doctors want to stop people from ending up in the hospital. They also want to prevent death. For years, the best tool we had was Paxlovid. It stops the virus from copying itself inside your cells.

However, the virus keeps changing. New versions appear. At the same time, vaccines become more common. This mix makes it hard to know what to do.

If a vaccinated person gets the virus, their immune system usually steps in quickly. It creates antibodies that fight the infection. But sometimes, the virus is strong, or the immune system is tired. That is when people worry about needing extra help.

The Surprising Shift

In the past, we thought one size fits all. We gave the same strong medicine to everyone who tested positive.

But this new study tells a different story. It looked at people who were already protected by vaccines or past infections.

Think of your immune system like a security team. When you get vaccinated, you hire more guards. These guards recognize the virus and stop it before it causes big trouble.

Paxlovid is like a tool that helps the guards work faster. It stops the virus from making copies of itself.

For unvaccinated people, the security team is small. They need the tool to survive. But for vaccinated people, the security team is large. They can often handle the virus on their own without the tool.

Researchers ran two big trials in the United Kingdom and Canada. They called them PANORAMIC and CanTreatCOVID.

They studied over 4,000 adults. These people were at higher risk because of their age or health conditions. They were all in the community, not in hospitals yet.

They had tested positive for the virus. They had been feeling sick for five days or less. This is the critical window where medicine works best.

Participants were split into two groups. One group took Paxlovid twice a day for five days. The other group took their usual care, which meant no special antiviral pill.

The main question was simple: Did the pill stop people from going to the hospital or dying?

In the UK trial, the results were very close. Only 0.8% of people taking the pill ended up in the hospital or died. In the group that did not take the pill, 0.7% had the same outcome.

The difference was so small that it was likely just chance. The study could not prove the pill helped in this specific group.

In the Canadian trial, the numbers looked slightly different. 0.6% of the pill group had bad outcomes. 1.2% of the usual care group did.

This looked like the pill helped. But the numbers were still very low overall. The study could not say for sure that the pill made a big difference.

This doesn't mean this treatment is available yet.

The Real-World Picture

There was a small extra study that looked at the virus itself. It found that the pill did lower the amount of virus in the body.

So, the medicine still works on the virus. But it does not seem to change the final outcome for vaccinated people.

Experts say this makes sense. If your immune system is strong, you do not need the extra push. Giving the pill to everyone might not be the best use of resources.

If you are vaccinated and you test positive, do not panic. Your body is likely ready to fight this off.

You should still call your doctor if you feel very sick. They can check your oxygen levels and your general health.

For now, the main advice stands: Stay up to date with your vaccines. This is the single best thing you can do to protect yourself.

If you are unvaccinated or have a weak immune system, talk to your doctor about Paxlovid. It may still be the right choice for you.

This study was very large, but it has limits. It only looked at people who were already vaccinated or had had the virus.

It did not look at people who were completely unvaccinated and had never had the virus. Those people might still need the pill.

Also, the study was open-label. This means the doctors knew who took the pill. This can sometimes change how patients feel or report symptoms.

Science moves fast. We are learning more every day about how the virus behaves and how our bodies respond.

This study helps doctors make better choices. It means we can save the pill for those who need it most.

For vaccinated people, the focus is on staying healthy and watching for warning signs. If you feel worse, seek help immediately.

Research continues to find the best ways to keep everyone safe. We are getting closer to a time when we can treat the virus with confidence and clarity.

Study Details

Study typeRct
Sample sizen = 3,516
EvidenceLevel 2
Follow-up600.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 days or less. The participants were randomly assigned to receive usual care plus nirmatrelvir (300 mg)-ritonavir (100 mg) twice a day for 5 days or to receive usual care alone. The primary outcome was hospitalization or death from any cause within 28 days after randomization. RESULTS: From December 8, 2021, to September 30, 2024, a total of 3516 participants in the PANORAMIC trial and 716 participants in the CanTreatCOVID trial underwent randomization. In the PANORAMIC trial, 14 of 1698 participants (0.8%) in the nirmatrelvir-ritonavir group and 11 of 1673 participants (0.7%) in the usual-care group were hospitalized or died (adjusted odds ratio, 1.18; 95% Bayesian credible interval, 0.55 to 2.62; probability of superiority, 0.334). In the CanTreatCOVID trial, 2 of 343 participants (0.6%) in the nirmatrelvir-ritonavir group and 4 of 324 participants (1.2%) in the usual-care group were hospitalized or died (adjusted odds ratio, 0.48; 95% Bayesian credible interval, 0.08 to 2.23; probability of superiority, 0.830). In a substudy involving 634 participants, viral load was reduced by the end of treatment with nirmatrelvir-ritonavir. Serious adverse events with nirmatrelvir-ritonavir were reported in 9 participants in the PANORAMIC trial and in 4 participants in the CanTreatCOVID trial. CONCLUSIONS: In two open-label trials, nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. (Funded by the National Institute for Health and Care Research, and others; PANORAMIC ISRCTN number, 2021-005748-31; CanTreatCOVID ClinicalTrials.gov number, NCT05614349.).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.